Pricing Log in Create free account

Citius Oncology, Inc. (CTOR) vs InterCure Ltd. (INCR)

Citius Oncology, Inc. and InterCure Ltd. are both Drug Manufacturers Specialty & Generic companies. Citius Oncology, Inc. is the larger, with a market value of $46.5M against $39.1M — 1.2× the size. Citius Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; InterCure Ltd. trades at 6.2×. InterCure Ltd. has the higher net margin (4.88% vs 0.00%) and the higher return on invested capital (0.00% vs −67.2%). Across the 11 metrics below, InterCure Ltd. leads on 11 and Citius Oncology, Inc. on 0.

Valuation

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
P/E n/m 6.23 20.55
P/S n/m 0.24 2.08
P/B 1.36 0.23 1.79
Price to free cash flow n/m n/m 16.29
EV/EBITDA n/m 6.17 12.22
EV/Sales n/m 0.56 2.87
Earnings yield (92.16%) 16.05% (15.94%)
Free cash flow yield (58.41%) (2.85%) 0.00%

Profitability

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
Gross margin — 32.74% 53.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 4.88% (2.45%)
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (126.58%) 0.00% (0.80%)
Return on assets (45.20%) 0.00% (1.67%)
Return on invested capital (67.15%) 0.00% 0.00%

Growth

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 16.15% 5.22%
EPS growth (last fiscal year) (9.68%) 52.50% 42.91%
Revenue growth, 5-year CAGR — 31.11% 7.24%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
Debt to equity 0.50 0.27 0.04
Current ratio 0.73 1.85 2.41
Net debt to EBITDA (0.40) (4.07) 1.01

Dividend

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
Market cap 46.50m 39.05m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack